{"id":744893,"date":"2014-12-06T13:00:00","date_gmt":"2014-12-06T13:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-investigating-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-in-patients-with-classical-hodgkin-lymphoma-presented-at-ash-annual-meeting\/"},"modified":"2023-03-22T00:04:48","modified_gmt":"2023-03-22T04:04:48","slug":"data-investigating-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-in-patients-with-classical-hodgkin-lymphoma-presented-at-ash-annual-meeting","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-investigating-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-in-patients-with-classical-hodgkin-lymphoma-presented-at-ash-annual-meeting\/","title":{"rendered":"Data Investigating KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s Anti-PD-1 Therapy, in Patients with Classical Hodgkin Lymphoma Presented at ASH Annual Meeting"},"content":{"rendered":"<p class=\"bwalignc\">       Overall Response Rate of 66 Percent Observed in KEYTRUDA-treated        Patients Whose Cancer Progressed on Brentuximab Vedotin     <\/p>\n<p class=\"bwalignc\">       Phase 2 Study Planned for the First Half of 2015 (KEYNOTE-087)     <\/p>\n<p>SAN FRANCISCO&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\" rel=\"noopener\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      announced today early study findings demonstrating that KEYTRUDA<sup>\u00ae <\/sup>(pembrolizumab),<br \/>\n      the company\u2019s anti-PD-1 therapy, achieved an overall response rate of 66<br \/>\n      percent, as assessed by International Harmonization Project response<br \/>\n      criteria (n=19\/29: 95% CI, 46-82), in transplant-ineligible and failure<br \/>\n      patients with relapsed\/refractory classical Hodgkin Lymphoma (cHL) whose<br \/>\n      disease progressed on or after treatment with brentuximab vedotin.<br \/>\n      Complete remission was achieved in 21 percent of patients (n=6\/29) in<br \/>\n      the study. At the time of analysis, 89 percent of responses were ongoing<br \/>\n      (n=17\/19) with the median duration of response not yet reached (range 1+<br \/>\n      to 185+ days). These early findings, from the ongoing Phase 1b<br \/>\n      KEYNOTE-013 study, were described for the first time as part of the<br \/>\n      official press program at the 56th American Society of Hematology (ASH)<br \/>\n      Annual Meeting in San Francisco (ABSTRACT #290) and will be presented in<br \/>\n      an oral session on December 8<sup>th<\/sup> by Dr. Craig Moskowitz,<br \/>\n      Memorial Sloan Kettering Cancer Center.\n    <\/p>\n<p>\n      \u201cThese early data presented at ASH 2014 are very promising and show<br \/>\n      response rates of 66 percent with pembrolizumab in patients with<br \/>\n      classical Hodgkin Lymphoma,\u201d said Dr. Craig Moskowitz, clinical<br \/>\n      director, division of hematologic oncology, Memorial Sloan Kettering<br \/>\n      Cancer Center. \u201cThere are few options for patients with multiple<br \/>\n      relapsed or refractory, classical Hodgkin Lymphoma, and pembrolizumab<br \/>\n      should continue to be studied for the treatment of this cancer.\u201d\n    <\/p>\n<p>\n      \u201cMerck\u2019s immuno-oncology development program spans more than 30<br \/>\n      different types of cancer including a focus on blood cancers like<br \/>\n      classical Hodgkin Lymphoma,\u201d said Dr. Alise Reicin, vice president,<br \/>\n      global clinical development, oncology, Merck Research Laboratories.<br \/>\n      \u201cResponse rates being observed with KEYTRUDA in these patients support<br \/>\n      the potential role of the PD-1 pathway in blood cancers. We look forward<br \/>\n      to initiating additional studies including a Phase 2 trial in classical<br \/>\n      Hodgkin Lymphoma in the first half of 2015.\u201d\n    <\/p>\n<p>\n      <b>Early Findings for Investigational Use of KEYTRUDA in<br \/>\n      Relapsed\/Refractory cHL<\/b>\n    <\/p>\n<p>\n      Data from a cohort of the ongoing Phase 1b KEYNOTE-013 study evaluated<br \/>\n      KEYTRUDA monotherapy at 10 mg\/kg every two weeks in patients with<br \/>\n      relapsed\/refractory classical Hodgkin Lymphoma who had progressed on or<br \/>\n      after treatment with brentuximab vedotin after failure of autologous<br \/>\n      stem-cell transplant, or who were transplant-ineligible (n=29).\n    <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tbody>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\" colspan=\"8\">\n<p class=\"bwcellpmargin\">\n            <b>Antitumor Activity by International Harmonization Project<br \/>\n            Response Criteria*<\/b>\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            <b>Transplant<\/b><br \/><b>Ineligible or<\/b><br \/><b>Refused<\/b><br \/><b>n=9<br \/>\n            (%)<\/b>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            <b>Transplant<\/b><br \/><b>Failure<\/b><br \/><b>n=20 (%)<\/b>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            <b>Total<\/b><br \/><b>n=29 (%)<\/b>\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">\n          Overall Response Rate\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          4 (44)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          15 (75)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          19 (66)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n          Complete Remission\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          2 (22)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          4 (20)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          6 (21)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n          Partial Remission\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          2 (22)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          11 (55)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          13 (45)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n          Stable Disease\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          3 (33)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          3 (15)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          6 (21)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n          Clinical Benefit Rate\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          7 (78)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          18 (90)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          25 (86)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">\n          Progressive Disease\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          2 (22)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          2 (10)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          4 (14)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl\" colspan=\"8\">\n<p class=\"bwcellpmargin\">\n            <b>*<\/b>Analysis cut-off date: November 17, 2014\n          <\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>\n      Median time to response was 12 weeks. In the transplant<br \/>\n      ineligible\/refusal patient group, eight patients were ineligible and one<br \/>\n      patient refused transplant, respectively. The patient who refused<br \/>\n      transplant achieved a complete remission.\n    <\/p>\n<p>\n      Adverse events were consistent with previously reported safety data for<br \/>\n      KEYTRUDA. The most common treatment-related adverse events (occurring in<br \/>\n      greater than or equal to two patients) included hypothyroidism (n=3),<br \/>\n      pneumonitis (n=3), constipation (n=2), diarrhea (n=2), nausea (n=2),<br \/>\n      hypercholesterolemia (n=2), hypertriglyceridemia (n=2) and hematuria<br \/>\n      (n=2). Sixteen patients (55%) experienced at least one treatment-related<br \/>\n      adverse event of any grade. Grade 3 treatment-related adverse events<br \/>\n      occurred in a total of three patients and included axillary pain,<br \/>\n      hypoxia, joint swelling, and pneumonitis. No Grade 4 treatment-related<br \/>\n      adverse events or treatment-related deaths were reported.\n    <\/p>\n<p>\n      <b>About the KEYNOTE-013 Study<\/b>\n    <\/p>\n<p>\n      KEYNOTE-013 is an ongoing multi-center, non-randomized Phase 1b trial of<br \/>\n      approximately 106 patients evaluating the safety, tolerability, and<br \/>\n      efficacy of KEYTRUDA monotherapy in patients with blood cancers,<br \/>\n      including myelodysplastic syndromes, multiple myeloma, Hodgkin lymphoma,<br \/>\n      mediastinal large B cell lymphoma and non-Hodgkin\u2019s lymphoma. The<br \/>\n      primary endpoints of the study include overall safety, tolerability, and<br \/>\n      complete remission rate (as measured by International Harmonization<br \/>\n      Project Response Criteria); secondary endpoints include overall response<br \/>\n      rate (ORR), progression-free survival (PFS), overall survival (OS) and<br \/>\n      duration of response.\n    <\/p>\n<p>\n      <b>About KEYTRUDA (pembrolizumab)<\/b>\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab) is a humanized monoclonal antibody that blocks<br \/>\n      the interaction between PD-1 and its ligands, PD-L1 and PD-L2. By<br \/>\n      binding to the PD-1 receptor and blocking the interaction with the<br \/>\n      receptor ligands, KEYTRUDA releases the PD-1 pathway-mediated inhibition<br \/>\n      of the immune response, including the anti-tumor immune response.\n    <\/p>\n<p>\n      KEYTRUDA is indicated in the United States at a dose of 2 mg\/kg every<br \/>\n      three weeks for the treatment of patients with unresectable or<br \/>\n      metastatic melanoma and disease progression following ipilimumab and, if<br \/>\n      BRAF V600 mutation positive, a BRAF inhibitor. This indication is<br \/>\n      approved under accelerated approval based on tumor response rate and<br \/>\n      durability of response. An improvement in survival or disease-related<br \/>\n      symptoms has not yet been established. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b>\n    <\/p>\n<p>\n      Pneumonitis occurred in 12 (2.9%) of 411 patients with advanced melanoma<br \/>\n      receiving KEYTRUDA (the approved indication in the United States),<br \/>\n      including Grade 2 or 3 cases in 8 (1.9%) and 1 (0.2%) patients,<br \/>\n      respectively. Monitor patients for signs and symptoms of pneumonitis.<br \/>\n      Evaluate suspected pneumonitis with radiographic imaging. Administer<br \/>\n      corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4<br \/>\n      pneumonitis.\n    <\/p>\n<p>\n      Colitis (including microscopic colitis) occurred in 4 (1%) of 411<br \/>\n      patients, including Grade 2 or 3 cases in 1 (0.2%) and 2 (0.5%) patients<br \/>\n      respectively, receiving KEYTRUDA. Monitor patients for signs and<br \/>\n      symptoms of colitis. Administer corticosteroids for Grade 2 or greater<br \/>\n      colitis. Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue<br \/>\n      KEYTRUDA for Grade 4 colitis.\n    <\/p>\n<p>\n      Hepatitis (including autoimmune hepatitis) occurred in 2 (0.5%) of 411<br \/>\n      patients, including a Grade 4 case in 1 (0.2%) patient, receiving<br \/>\n      KEYTRUDA. Monitor patients for changes in liver function. Administer<br \/>\n      corticosteroids for Grade 2 or greater hepatitis and, based on severity<br \/>\n      of liver enzyme elevations, withhold or discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Hypophysitis occurred in 2 (0.5%) of 411 patients, including a Grade 2<br \/>\n      case in 1 and a Grade 4 case in 1 (0.2% each) patient, receiving<br \/>\n      KEYTRUDA. Monitor for signs and symptoms of hypophysitis. Administer<br \/>\n      corticosteroids for Grade 2 or greater hypophysitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; withhold or discontinue for Grade 3; and permanently<br \/>\n      discontinue KEYTRUDA for Grade 4 hypophysitis.\n    <\/p>\n<p>\n      Nephritis occurred in 3 (0.7%) patients receiving KEYTRUDA, consisting<br \/>\n      of one case of Grade 2 autoimmune nephritis (0.2%) and two cases of<br \/>\n      interstitial nephritis with renal failure (0.5%), one Grade 3 and one<br \/>\n      Grade 4. Monitor patients for changes in renal function. Administer<br \/>\n      corticosteroids for Grade 2 or greater nephritis. Withhold KEYTRUDA for<br \/>\n      Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      Hyperthyroidism occurred in 5 (1.2%) of 411 patients, including Grade 2<br \/>\n      or 3 cases in 2 (0.5%) and 1 (0.2%) patients respectively, receiving<br \/>\n      KEYTRUDA. Hypothyroidism occurred in 34 (8.3%) of 411 patients,<br \/>\n      including a Grade 3 case in 1 (0.2%) patient, receiving KEYTRUDA.<br \/>\n      Thyroid disorders can occur at any time during treatment. Monitor<br \/>\n      patients for changes in thyroid function (at the start of treatment,<br \/>\n      periodically during treatment, and as indicated based on clinical<br \/>\n      evaluation) and for clinical signs and symptoms of thyroid disorders.<br \/>\n      Administer corticosteroids for Grade 3 or greater hyperthyroidism.<br \/>\n      Withhold KEYTRUDA for Grade 3; permanently discontinue KEYTRUDA for<br \/>\n      Grade 4 hyperthyroidism. Isolated hypothyroidism may be managed with<br \/>\n      replacement therapy without treatment interruption and without<br \/>\n      corticosteroids.\n    <\/p>\n<p>\n      Other clinically important immune-mediated adverse reactions can occur.<br \/>\n      The following clinically significant, immune-mediated adverse reactions<br \/>\n      occurred in less than 1% of patients treated with KEYTRUDA: exfoliative<br \/>\n      dermatitis, uveitis, arthritis, myositis, pancreatitis, hemolytic<br \/>\n      anemia, partial seizures arising in a patient with inflammatory foci in<br \/>\n      brain parenchyma, adrenal insufficiency, myasthenic syndrome, optic<br \/>\n      neuritis, and rhabdomyolysis.\n    <\/p>\n<p>\n      For suspected immune-mediated adverse reactions, ensure adequate<br \/>\n      evaluation to confirm etiology or exclude other causes. Based on the<br \/>\n      severity of the adverse reaction, withhold KEYTRUDA and administer<br \/>\n      corticosteroids. Upon improvement of the adverse reaction to Grade 1 or<br \/>\n      less, initiate corticosteroid taper and continue to taper over at least<br \/>\n      1 month. Restart KEYTRUDA if the adverse reaction remains at Grade 1 or<br \/>\n      less. Permanently discontinue KEYTRUDA for any severe or Grade 3<br \/>\n      immune-mediated adverse reaction that recurs and for any<br \/>\n      life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA may cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      For the treatment of advanced melanoma, KEYTRUDA was discontinued for<br \/>\n      adverse reactions in 6% of 89 patients who received the recommended dose<br \/>\n      of 2 mg\/kg and 9% of 411 patients across all doses studied. Serious<br \/>\n      adverse reactions occurred in 36% of patients receiving KEYTRUDA. The<br \/>\n      most frequent serious adverse drug reactions reported in 2% or more of<br \/>\n      patients were renal failure, dyspnea, pneumonia, and cellulitis.\n    <\/p>\n<p>\n      The most common adverse reactions (reported in \u226520% of patients) were<br \/>\n      fatigue (47%), cough (30%), nausea (30%), pruritus (30%), rash (29%),<br \/>\n      decreased appetite (26%), constipation (21%), arthralgia (20%), and<br \/>\n      diarrhea (20%).\n    <\/p>\n<p>\n      The recommended dose of KEYTRUDA is 2 mg\/kg administered as an<br \/>\n      intravenous infusion over 30 minutes every three weeks until disease<br \/>\n      progression or unacceptable toxicity. No formal pharmacokinetic drug<br \/>\n      interaction studies have been conducted with KEYTRUDA. It is not known<br \/>\n      whether KEYTRUDA is excreted in human milk. Because many drugs are<br \/>\n      excreted in human milk, instruct women to discontinue nursing during<br \/>\n      treatment with KEYTRUDA. Safety and effectiveness of KEYTRUDA have not<br \/>\n      been established in pediatric patients.\n    <\/p>\n<p>\n      <b>About Lymphoma<\/b>\n    <\/p>\n<p>\n      Lymphoma is a type of blood cancer that affects the lymphatic system,<br \/>\n      which removes excess fluids from the body and produces immune cells.<br \/>\n      Abnormal lymphocytes, a type of white blood cell that fight infection,<br \/>\n      become lymphoma cells, which multiply and collect in the lymph nodes and<br \/>\n      other tissues. Over time, these cancerous cells impair the immune system.<sup>1<\/sup><br \/>\n      In 2012, more than 450,000 people were estimated to have been diagnosed<br \/>\n      with lymphoma (Hodgkin lymphoma and non-Hodgkin lymphoma); more than<br \/>\n      225,000 people died from the condition.<sup>2<\/sup> Hodgkin lymphoma is<br \/>\n      different from other lymphomas because it contains Reed-Sternberg cells,<br \/>\n      a specific type of large cancer cells.<sup>3<\/sup>\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today\u2019s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to healthcare through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2F&amp;esheet=50997164&amp;newsitemid=20141206005008&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=1&amp;md5=87cf0a7d92e89d0276d4eb88d6c488bf\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fcp.mcafee.com%2Fd%2F1jWVIedEI8Ie3D1Ob9KVJd5AsYeKCYedFEIzDxRSmkjqqb8VUttdVUSzt4QsEKnsohdG_6NmIblfGhbj_lgkoIIhfGgQ_BPpyON4-F3j-ndKKnojvovW_3AT-LsKCO-ZOb8UtORQr8EGTjjVkffGhBrwqrhdLCXCXCOsVHkiP9C9jDYunNnUSaCXlrze7Bxmdoquxk5a_6NnBPr3XzPVIn0l8Qg0eTZ9OH2yhEwd40oxqFZi9oQg1dp3p-Aq81se43h04EX2t3h0cN_iIOsqJAipEw19fUWImd40tZ94orelo6y2tjh01gQ1Mi2MC721EwtH4Qg221DomZ0Qg0Mo4wG96QrzztxwgD7GV&amp;esheet=50997164&amp;newsitemid=20141206005008&amp;lan=en-US&amp;anchor=Twitter&amp;index=2&amp;md5=9e430443a8727d3235068fa645f991d4\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fcp.mcafee.com%2Fd%2F1jWVIgdEI8Ie3D1Ob9KVJd5AsYeKCYedFEIzDxRSmkjqqb8VUttdVUSzt4QsEKnsohdG_6NmIblfGhbj_lgkoIIhfGgQ_BPpyON4-F3j-ndKKnojvovW_3AT-LsKCO-ZOb8UtORQr8EGTjjVkffGhBrwqrjdLCXCXCM0jKSYxmFnBYl-dyF3P7DDCXlrze7Bxmdoquxk5a_6NnBPr3XzPVIn0l8Qg0eTZ9OH2yhEwd40oxqFZi9oQg1dp3p-Aq81se43h04EX2t3h0cN_iIOsqJAipEw19fUWImd40tZ94orelo6y2tjh01gQ1Mi2MC721EwtH4Qg221DomZ0Qg0Mo4wG96Qrzzu-jj&amp;esheet=50997164&amp;newsitemid=20141206005008&amp;lan=en-US&amp;anchor=Facebook&amp;index=3&amp;md5=6f341782aeb14e9edb2582348cb6e780\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fcp.mcafee.com%2Fd%2FavndzgA76Qm4m71PwV5ATsSCyOeu7nju76QQmhPMWXba9Jd5AsYeKCYYrhKyqeknbKc8CRvzoHm5GDR8BF_GEacmm8DR8qvOVINpoyvkxF_bCTnbI9LIfZvxOr_nKnjpvuV5AseVqWdAklrFFYG7DR8OJMddICTPtPtPo08JlKrp3-nNnUSaCXlrze7Bxmdoquxk5a_6NnBPr3XzPVIn0l8Qg0eTZ9OH2yhEwd40oxqFZi9oQg1dp3p-Aq81se43h04EX2t3h0cN_iIOsqJAipEw19fUWImd40tZ94orelo6y2tjh01gQ1Mi2MC721EwtH4Qg221DomZ0Qg0Mo4wG96QrzzqvgF&amp;esheet=50997164&amp;newsitemid=20141206005008&amp;lan=en-US&amp;anchor=YouTube&amp;index=4&amp;md5=433cb09a2f733951d4c7aa581100075a\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Our Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into biomedical<br \/>\n      innovations to help people with cancer worldwide. For Merck Oncology,<br \/>\n      helping people fight cancer is our passion, supporting accessibility to<br \/>\n      our cancer medicines is our commitment, and pursuing research in<br \/>\n      immuno-oncology is our focus to potentially bring new hope to people<br \/>\n      with cancer. For more information about our oncology clinical trials,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=50997164&amp;newsitemid=20141206005008&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=5&amp;md5=c192178ee896960a76c9e8560294b9ea\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include, but are not limited to, general<br \/>\n      industry conditions and competition; general economic factors, including<br \/>\n      interest rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and healthcare legislation in the<br \/>\n      United States and internationally; global trends toward healthcare cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2013 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=50997164&amp;newsitemid=20141206005008&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=6&amp;md5=450058269f435d1976490faedfca339f\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=50997164&amp;newsitemid=20141206005008&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=7&amp;md5=0cdb31268398471a6717da65aa26b8c1\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><\/a><b><br \/>\n      and the Medication Guide for KEYTRUDA at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=50997164&amp;newsitemid=20141206005008&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=8&amp;md5=1566ba0ae80bdd1cfe8d718358ae5e04\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><\/a><b>.<\/b>\n    <\/p>\n<p>\n      <sup>1<\/sup> American Society of Hematology. Blood Cancers. Available<br \/>\n      at: <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.hematology.org%2FPatients%2FCancers%2F&amp;esheet=50997164&amp;newsitemid=20141206005008&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.hematology.org%2FPatients%2FCancers%2F&amp;index=9&amp;md5=77332e393ab326d281a62cb9842b1796\" rel=\"nofollow\">http:\/\/www.hematology.org\/Patients\/Cancers\/<\/a>.<br \/>\n      Accessibility verified on November 3, 2014.&nbsp;<br \/><sup>2<\/sup><br \/>\n      GLOBOCAN. World. Available at: <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fglobocan.iarc.fr%2FPages%2Ffact_sheets_population.aspx&amp;esheet=50997164&amp;newsitemid=20141206005008&amp;lan=en-US&amp;anchor=http%3A%2F%2Fglobocan.iarc.fr%2FPages%2Ffact_sheets_population.aspx&amp;index=10&amp;md5=ddcf2674f767a0a6afed69ddaae3b2ae\" rel=\"nofollow\">http:\/\/globocan.iarc.fr\/Pages\/fact_sheets_population.aspx<\/a>.<br \/>\n      Accessibility verified on November 3, 2014.&nbsp;<br \/><sup>3<\/sup> MD<br \/>\n      Anderson Cancer Center. Hodgkin\u2019s Lymphoma. Available at: <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mdanderson.org%2Fpatient-and-cancer-information%2Fcancer-information%2Fcancer-types%2Fhodgkins-lymphoma%2Findex.html&amp;esheet=50997164&amp;newsitemid=20141206005008&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.mdanderson.org%2Fpatient-and-cancer-information%2Fcancer-information%2Fcancer-types%2Fhodgkins-lymphoma%2Findex.html&amp;index=11&amp;md5=4ff81fead6dc659cbd55af47faed310c\" rel=\"nofollow\">http:\/\/www.mdanderson.org\/patient-and-cancer-information\/cancer-information\/cancer-types\/hodgkins-lymphoma\/index.html<\/a>.\n    <\/p>\n<p>\n      <b>KEYTRUDA<\/b><sup><b>\u00ae<\/b><\/sup><b> is a registered trademark of Merck<br \/>\n      &amp; Co., Inc., Whitehouse Station, N.J., USA<\/b>\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20141206005008r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Media:<br \/>Pamela Eisele, 267-305-3558<br \/>or<br \/>Claire Mulhearn,        908-236-1118<br \/>or<br \/>Investor:<br \/>Joseph Romanelli, 908-740-1986<br \/>or<br \/>Justin        Holko, 908-740-1879     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today early study findings demonstrating that KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, achieved an overall response rate of 66 percent, as assessed by International Harmonization Project response criteria (n=19\/29: 95% CI, 46-82), in transplant-ineligible and failure patients with relapsed\/refractory classical Hodgkin Lymphoma (cHL) whose disease progressed on or after treatment with brentuximab vedotin. Complete remission was achieved in 21 percent of patients (n=6\/29) in the study. At the time of analysis, 89 percent of responses were ongoing (n=17\/19) with the median duration of response not yet reached (range 1+ to 185+ days). These early findings, from the ongoing Phase 1b KEYNOTE-013 study, were described for the first time as part of the official press program at the 56th American Society of Hematology (ASH) Annual Meeting in San Francisco (ABSTRACT #290) and will be presented in<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,138,289],"class_list":["post-744893","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-oncology-newsroom","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Data Investigating KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s Anti-PD-1 Therapy, in Patients with Classical Hodgkin Lymphoma Presented at ASH Annual Meeting - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-investigating-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-in-patients-with-classical-hodgkin-lymphoma-presented-at-ash-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Data Investigating KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s Anti-PD-1 Therapy, in Patients with Classical Hodgkin Lymphoma Presented at ASH Annual Meeting - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today early study findings demonstrating that KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, achieved an overall response rate of 66 percent, as assessed by International Harmonization Project response criteria (n=19\/29: 95% CI, 46-82), in transplant-ineligible and failure patients with relapsed\/refractory classical Hodgkin Lymphoma (cHL) whose disease progressed on or after treatment with brentuximab vedotin. Complete remission was achieved in 21 percent of patients (n=6\/29) in the study. At the time of analysis, 89 percent of responses were ongoing (n=17\/19) with the median duration of response not yet reached (range 1+ to 185+ days). These early findings, from the ongoing Phase 1b KEYNOTE-013 study, were described for the first time as part of the official press program at the 56th American Society of Hematology (ASH) Annual Meeting in San Francisco (ABSTRACT #290) and will be presented in\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-investigating-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-in-patients-with-classical-hodgkin-lymphoma-presented-at-ash-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"11 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/data-investigating-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-in-patients-with-classical-hodgkin-lymphoma-presented-at-ash-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/data-investigating-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-in-patients-with-classical-hodgkin-lymphoma-presented-at-ash-annual-meeting\\\/\",\"name\":\"Data Investigating KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s Anti-PD-1 Therapy, in Patients with Classical Hodgkin Lymphoma Presented at ASH Annual Meeting - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2014-12-06T13:00:00+00:00\",\"dateModified\":\"2023-03-22T04:04:48+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/data-investigating-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-in-patients-with-classical-hodgkin-lymphoma-presented-at-ash-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/data-investigating-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-in-patients-with-classical-hodgkin-lymphoma-presented-at-ash-annual-meeting\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/data-investigating-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-in-patients-with-classical-hodgkin-lymphoma-presented-at-ash-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Data Investigating KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s Anti-PD-1 Therapy, in Patients with Classical Hodgkin Lymphoma Presented at ASH Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Data Investigating KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s Anti-PD-1 Therapy, in Patients with Classical Hodgkin Lymphoma Presented at ASH Annual Meeting - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-investigating-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-in-patients-with-classical-hodgkin-lymphoma-presented-at-ash-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Data Investigating KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s Anti-PD-1 Therapy, in Patients with Classical Hodgkin Lymphoma Presented at ASH Annual Meeting - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today early study findings demonstrating that KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, achieved an overall response rate of 66 percent, as assessed by International Harmonization Project response criteria (n=19\/29: 95% CI, 46-82), in transplant-ineligible and failure patients with relapsed\/refractory classical Hodgkin Lymphoma (cHL) whose disease progressed on or after treatment with brentuximab vedotin. Complete remission was achieved in 21 percent of patients (n=6\/29) in the study. At the time of analysis, 89 percent of responses were ongoing (n=17\/19) with the median duration of response not yet reached (range 1+ to 185+ days). These early findings, from the ongoing Phase 1b KEYNOTE-013 study, were described for the first time as part of the official press program at the 56th American Society of Hematology (ASH) Annual Meeting in San Francisco (ABSTRACT #290) and will be presented in","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-investigating-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-in-patients-with-classical-hodgkin-lymphoma-presented-at-ash-annual-meeting\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:48+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-investigating-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-in-patients-with-classical-hodgkin-lymphoma-presented-at-ash-annual-meeting\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-investigating-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-in-patients-with-classical-hodgkin-lymphoma-presented-at-ash-annual-meeting\/","name":"Data Investigating KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s Anti-PD-1 Therapy, in Patients with Classical Hodgkin Lymphoma Presented at ASH Annual Meeting - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2014-12-06T13:00:00+00:00","dateModified":"2023-03-22T04:04:48+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-investigating-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-in-patients-with-classical-hodgkin-lymphoma-presented-at-ash-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-investigating-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-in-patients-with-classical-hodgkin-lymphoma-presented-at-ash-annual-meeting\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/data-investigating-keytruda-pembrolizumab-mercks-anti-pd-1-therapy-in-patients-with-classical-hodgkin-lymphoma-presented-at-ash-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Data Investigating KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s Anti-PD-1 Therapy, in Patients with Classical Hodgkin Lymphoma Presented at ASH Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"d5b238ff-e5b0-4e8b-b97b-f898a7d57a09","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Data-Investigating-KEYTRUDA-pembrolizumab-Mercks-Anti-PD-1-Therapy-in-Patients-with-Classical-Hodgkin-Lymphoma-Presented-at-ASH-Annua-JRKKY.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744893","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744893\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=744893"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=744893"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}